Published • loading... • Updated
Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026
- Antengene announced that it will present the latest preclinical results for ATG-207 at the 2026 American College of Rheumatology Annual Meeting in Orlando, Florida.
- ATG-207 is a proprietary αCD3-TGF-β bifunctional fusion protein being developed for T cell–mediated autoimmune diseases.
- Researchers created ATG-207 by adding a peptide-masked, TGFβRIII-biased TGF-β domain to an anti-CD3 antibody.
- In mouse models, a surrogate version of ATG-207 showed therapeutic effects.
Insights by Ground AI
32 Articles
32 Articles
The Herald-Dispatch+31 Reposted by 31 other sources
Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026
SHANGHAI and HONG KONG, Oct. 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological…
Coverage Details
Total News Sources32
Leaning Left5Leaning Right1Center20Last UpdatedBias Distribution77% Center
Bias Distribution
- 77% of the sources are Center
77% Center
L 19%
C 77%
Factuality
To view factuality data please Upgrade to Premium
